Literature DB >> 31396353

MicroRNA-765 alleviates the malignant progression of breast cancer via interacting with EZH1.

Zhen Zeng1,2, Yichen Yang1,2, Hengyu Wu2.   

Abstract

To detect the expression pattern of microRNA-765 in breast cancer (BCa) and its regulatory effect on the disease progression. Expression level of microRNA-765 in 66 paired BCa tissues and matched normal tissues was detected by qRT-PCR. The relationship between microRNA-765 level and clinical data of BCa patients was analyzed. Subsequently, microRNA-765 level in BCa cell lines was examined as well. Changes in proliferative, migratory and invasive abilities in MCF-7 and SKBR3 cells either overexpressing microRNA-765 or not were evaluated. Furthermore, expression level of EZH1 in BCa tissues and cell lines was determined. The regulatory interaction between microRNA-765 and EZH1 was identified. Finally, the role of microRNA-765/EZH1 axis in the progression of BCa was assessed. MicroRNA-765 was downregulated in BCa tissues relative to matched normal ones. BCa patients expressing low expression of microRNA-765 presented higher tumor stage, higher metastatic rate and worse overall survival. Overexpression of microRNA-765 attenuated proliferative, migratory and invasive abilities in MCF-7 and SKBR3 cells. In addition, EZH1 was upregulated in BCa tissues and cell lines. EZH1 level was negatively regulated by microRNA-765 in BCa. Overexpression of EZH1 reversed the inhibitory effects of microRNA-765 on malignant progression of BCa. MicroRNA-765 is downregulated in BCa and closely correlated to tumor stage, lymphatic metastasis, distant metastasis and poor prognosis of BCa patients. Overexpression of microRNA-765 attenuates the malignant progression of BCa through negatively regulating EZH1.

Entities:  

Keywords:  EZH1; MicroRNA-765; breast cancer; metastasis; proliferation

Year:  2019        PMID: 31396353      PMCID: PMC6684906     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  20 in total

Review 1.  miRNAs as novel biomarkers in the management of prostate cancer.

Authors:  Xavier Filella; Laura Foj
Journal:  Clin Chem Lab Med       Date:  2017-05-01       Impact factor: 3.694

2.  miRNA and cancer; computational and experimental approaches.

Authors:  Yusuf Tutar
Journal:  Curr Pharm Biotechnol       Date:  2014       Impact factor: 2.837

3.  Breast Cancer Survivorship: Where Are We Today?

Authors:  Patricia A Ganz; Pamela J Goodwin
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

4.  Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer.

Authors:  Zebo Huang; Danxia Zhu; Lirong Wu; Mingfeng He; Xin Zhou; Lan Zhang; Huo Zhang; Weiwei Wang; Jun Zhu; Wenfang Cheng; Yan Chen; Yong Fan; Lianwen Qi; Yin Yin; Wei Zhu; Yongqian Shu; Ping Liu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10-18       Impact factor: 4.254

Review 5.  Descriptive epidemiology of breast cancer in China: incidence, mortality, survival and prevalence.

Authors:  Tong Li; Claudia Mello-Thoms; Patrick C Brennan
Journal:  Breast Cancer Res Treat       Date:  2016-08-25       Impact factor: 4.872

Review 6.  The nuclear envelope environment and its cancer connections.

Authors:  Kin-Hoe Chow; Rachel E Factor; Katharine S Ullman
Journal:  Nat Rev Cancer       Date:  2012-02-16       Impact factor: 60.716

Review 7.  Clinical Diagnosis and Management of Breast Cancer.

Authors:  Elizabeth S McDonald; Amy S Clark; Julia Tchou; Paul Zhang; Gary M Freedman
Journal:  J Nucl Med       Date:  2016-02       Impact factor: 10.057

8.  Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.

Authors:  Marilyn L Kwan; Candyce H Kroenke; Carol Sweeney; Philip S Bernard; Erin K Weltzien; Adrienne Castillo; Rachel E Factor; Kaylynn S Maxfield; Inge J Stijleman; Lawrence H Kushi; Charles P Quesenberry; Laurel A Habel; Bette J Caan
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

9.  Novel miRNA-mRNA interactions conserved in essential cancer pathways.

Authors:  Eduardo Andrés-León; Ildefonso Cases; Sergio Alonso; Ana M Rojas
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

10.  Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer.

Authors:  Yuet-Kin Leung; Queeny Kwan-Yi Chan; Chi-Fai Ng; Fanny Man-Ting Ma; Ho-Man Tse; Ka-Fai To; Jodi Maranchie; Shuk-Mei Ho; Kin-Mang Lau
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

View more
  5 in total

1.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

Review 2.  Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.

Authors:  Deniz Mortazavi; Behnoush Sohrabi; Meysam Mosallaei; Ziba Nariman-Saleh-Fam; Milad Bastami; Yaser Mansoori; Abdolreza Daraei; Sepideh Zununi Vahed; Shadan Navid; Zahra Saadatian; Tannaz Jamialahmadi; Yong Teng; Amirhossein Sahebkar
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

3.  MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1.

Authors:  Qianqian Zhang; Xiaohong Deng; Xiuxin Tang; Ying You; Meihua Mei; Danping Liu; Lian Gui; Yan Cai; Xiaoping Xin; Xiaoshun He; Junqi Huang
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

4.  Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients.

Authors:  Wei Peng; Wei Tang; Jian-Di Li; Rong-Quan He; Jia-Yuan Luo; Zu-Xuan Chen; Jiang-Hui Zeng; Xiao-Hua Hu; Jin-Cai Zhong; Yang Li; Fu-Chao Ma; Tian-Yi Xie; Su-Ning Huang; Lian-Ying Ge
Journal:  PeerJ       Date:  2022-07-12       Impact factor: 3.061

Review 5.  miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment.

Authors:  Erik Kudela; Marek Samec; Lenka Koklesova; Alena Liskova; Peter Kubatka; Erik Kozubik; Tomas Rokos; Terezia Pribulova; Eva Gabonova; Marek Smolar; Kamil Biringer
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.